Phthalimide‐tethered isatins as novel poly(ADP‐ribose) polymerase inhibitors: Design, synthesis, biological evaluations, and molecular modeling investigations

Abstract

AbstractHumanity is currently facing various diseases with significant mortality rates, particularly those associated with malignancies. Numerous enzymes and proteins have been identified as highly promising targets for the treatment of cancer. The poly(ADP‐ribose) polymerases (PARPs) family comprises 17 members which are essential in DNA damage repair, allowing the survival of cancer cells. Unlike other PARP family members, PARP‐1 and, to a lesser extent, PARP‐2 show more than 90% activity in response to DNA damage. PARP‐1 levels were shown to be elevated in various tumor cells, including breast, lung, ovarian, and prostate cancer and melanomas. Accordingly, novel series of phthalimide‐tethered isatins (6a‐n, 10a‐e, and 11a‐e) were synthesized as potential PARP‐1 inhibitors endowed with anticancer activity. All the synthesized molecules were assessed against PARP‐1, where compounds 6f and 10d showed nanomolar activities with IC50 = 15.56 ± 2.85 and 13.65 ± 1.42 nM, respectively. Also, the assessment of the antiproliferative effects of the synthesized isatins was conducted on four cancer cell lines: leukemia (K‐562), liver (HepG2), and breast (MCF‐7 and HCC1937) cancers. Superiorly, compounds 6f and 10d demonstrated submicromolar IC50 values against breast cancer MCF‐7 (IC50 = 0.92 ± 0.18 and 0.67 ± 0.12 µM, respectively) and HCC1937 (IC50 = 0.88 ± 0.52 and 0.53 ± 0.11 µM, respectively) cell lines. In addition, compounds 6f and 10d induced arrest in the G2/M phase of the cell cycle as compared to untreated cells. Finally, in silico studies, including docking and molecular dynamic simulations, were performed to justify the biological results.